Image

Characterisation of Endothelial Cells in Different Inflammatory Pathologies

Characterisation of Endothelial Cells in Different Inflammatory Pathologies

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The goal of this observational study is to characterise changes in gene expression in endothelial cells in patients with either sepsis or post major abdominal surgery.

The main question we plan to answer is: 'What molecular pathways are differentially expressed during inflammatory pathologies?'

Description

The immune system is a complex network of cells and molecules that protects the body from infection and injury. When the immune system is activated, it produces inflammation, which is a natural response to help heal the body. However, too much inflammation can be harmful and lead to serious complications, such as sepsis, low blood pressure, organ failure and death.

The interaction of cells that line the blood vessels (endothelial cells, EC) with the immune system, is believed to be the root cause of these symptoms. When exposed to inflammation, the instructional molecules (RNA) inside the EC change. This leads to a change of operation promoting the severe symptoms previously mentioned.

Researchers have developed new safe techniques to collect these cells from the blood vessels of patients to study disorders like diabetes, heart disease and stroke. This technique involves gently inserting a metal guidewire into an arm vein to collect ECs.

This study plans to collect ECs from patients undergoing surgery or admitted to intensive care. We also plan to collect control samples from healthy volunteers. Samples will be collected over the duration of the patients to RSFT. The RNA will be removed from the cells and counted to highlight changes in instructions in the cells.

Data from this study will potentially highlight new pathways involved in inflammation and help classify how some patients will react to current treatments. To obtain this data, this study will be split into 2 parts. Part 1 focuses on collecting one sample from a patient when they are at their most unwell states and comparing that to a sample from a healthy person. Part 2 will focus on key mRNA molecules identified during Part 1 and identifying how their expression changes over time.

Eligibility

Inclusion Criteria:

Healthy volunteer

  • Adult ≥ 18 years
  • Able and willing to give consent

Surgical patients

  • Adult ≥ 18 years
  • Patients admitted to RSFT for planned major surgery

Critically ill patients

  • Adult ≥ 18 years
  • Emergency admission to ICU at RSFT
  • Meets the sepsis 3.0 definition

Exclusion Criteria:

Healthy volunteer

  • Not currently a patient within the hospital
  • Absence of inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, diabetes, cardiovascular disease and CKD.
  • Not on immunomodulatory medications, such as corticosteroids
  • History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation)

Surgical patients

  • Patients with restricted liberty, prisoners or under legal protection
  • Anticipated prohibitively difficult venous cannulation
  • Presenting with inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, sepsis, diabetes with end organ damage, cardiovascular disease and CKD
  • Currently prescribed immunomodulatory medication or immunocompromised
  • Received chemotherapy within 2 weeks of predicted sampling
  • Receiving vasopressor support prior to surgery
  • History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation)

Critically ill patients

  • Patients with restricted liberty, prisoners or under legal protection• Anticipated prohibitively difficult venous cannulation
  • Presenting with inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, diabetes with end organ damage, cardiovascular disease and CKD.
  • Currently prescribed immunomodulatory medication or immunocompromised
  • Received chemotherapy within 2 weeks of predicted sampling.
  • History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation)

Study details
    Sepsis
    Vasoplegia

NCT06613256

Royal Surrey County Hospital NHS Foundation Trust

9 September 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.